T
Tetra Pharm Technologies
Tetra Pharm is a research focused biopharmaceutical company delivering cannabinoid based therapies
About Tetra Pharm Technologies
Tetra Pharm Technologies is a Danish biopharmaceutical startup, established in 2018 and based north of Copenhagen. The company specializes in the development and manufacturing of pharmaceutical drugs that target the endocannabinoid system. These drugs are primarily aimed at treating neuropathic pain, neurological diseases, and mental health disorders.
Tetra Pharm operates in the pharmaceutical industry, specifically within the niche of endocannabinoid system-targeting drugs. This is a relatively new and rapidly evolving field, positioning Tetra Pharm at the forefront of undiscovered territory. The company's primary clients are likely to be healthcare providers and patients suffering from the aforementioned conditions.
The business model of Tetra Pharm is based on research, development, and manufacturing of pharmaceutical drugs. The company generates revenue by selling these drugs to healthcare providers. Additionally, Tetra Pharm is committed to being a sustainable business, indicating a potential focus on environmentally friendly practices in its operations.
In terms of societal impact, Tetra Pharm takes its role seriously. The company is dedicated to improving the quality of life for patients and is conscious of its responsibility to contribute positively to the world.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Hillerød, Denmark
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Cannabis, Tech for Biotech and Pharma, Medicinal Cannabis, Nordic Rising Star 2022, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2023 | $9.9M | $40M | Undisclosed | ↗ |
| SEED✓Equity / VC | Dec 2021 | $2.2M | $8.8M | Leafy Tunnel · Enexis | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Tetra Pharm Technologies is 550 monthly website visits, down 63.3% over the last three months. Tetra Pharm Technologies's team declined 14.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Leafy Tunnel
Enexis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tetra Pharm Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tetra Pharm Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.